Eschalier; Alain

Patent Applications and Registrations

Patent applications and USPTO patent grants for Eschalier; Alain.The latest application filed is for "centrally acting acetylcholinesterase inhibitors for the prevention and/or treatment of chemically induced neuropathies and the symptoms thereof, and corresponding compositions, uses, methods and kit".

Company Profile

1.7.9

Eschalier; Alain - Chamalieres FR

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Pain relief compounds Grant 10,214,476 - Ducki , et al. Feb	2019-02-26
Centrally Acting Acetylcholinesterase Inhibitors For The Prevention And/or Treatment Of Chemically Induced Neuropathies And The Symptoms Thereof, And Corresponding Compositions, Uses, Methods And Kit App 20180085360 - ESCHALIER; ALAIN ; et al.	2018-03-29
Centrally Acting Acetylcholinesterase Inhibitors For The Prevention And/or Treatment Of Chemically Induced Neuropathies And The Symptoms Thereof, And Corresponding Compositions, Uses, Methods And Kit App 20170128428 - ESCHALIER; ALAIN ; et al.	2017-05-11
Use of riluzole for treating or preventing the adverse effects of antineoplastic agents Grant 9,511,045 - Busserolles , et al. December 6, 2	2016-12-06
Use of K2P potassium channel activators as antalgics Grant 9,448,242 - Eschalier , et al. September 20, 2	2016-09-20
Hypophosphorous acid derivatives having antihyperalgic activity and biological applications thereof Grant 9,212,196 - Acher , et al. December 15, 2	2015-12-15
Pain Relief Compounds App 20150274633 - DUCKI; Sylvie ; et al.	2015-10-01
Pain Relief Compounds App 20150038466 - Ducki; Sylvie ; et al.	2015-02-05
Hypophosphorous Acid Derivatives Having Antihyperalgic Activity And Biological Applications Thereof App 20140107078 - Acher; Francine ; et al.	2014-04-17
Use Of Riluzole For Treating Or Preventing The Adverse Effects Of Antineoplastic Agents App 20130064775 - Busserolles; Jerome ; et al.	2013-03-14
Use of K2P Potassium Channel Activators as Antalgics App 20120260354 - Eschalier; Alain ; et al.	2012-10-11

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.